Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Treasury Shares: 2016-2024

  • Rhythm Pharmaceuticals' Treasury Shares rose 65.37% to $1.8 million in Q4 2024 from the same period last year, while for Dec 2024 it was $1.8 million, marking a year-over-year increase of 65.37%. This contributed to the annual value of $1.8 million for FY2024, which is 65.37% up from last year.
  • Per Rhythm Pharmaceuticals' latest filing, its Treasury Shares stood at $1.8 million for Q4 2024, which was up 65.37% from $1.1 million recorded in Q4 2023.
  • Over the past 5 years, Rhythm Pharmaceuticals' Treasury Shares peaked at $1.8 million during Q4 2024, and registered a low of $804,797 during Q4 2022.
  • For the 3-year period, Rhythm Pharmaceuticals' Treasury Shares averaged around $1.2 million, with its median value being $1.1 million (2023).
  • As far as peak fluctuations go, Rhythm Pharmaceuticals' Treasury Shares declined by 15.83% in 2022, and later surged by 65.37% in 2024.
  • Rhythm Pharmaceuticals' Treasury Shares (Quarterly) stood at $956,145 in 2021, then fell by 15.83% to $804,797 in 2022, then spiked by 37.25% to $1.1 million in 2023, then spiked by 65.37% to $1.8 million in 2024.
  • Its Treasury Shares stands at $1.8 million for Q4 2024, versus $1.1 million for Q4 2023 and $804,797 for Q4 2022.